Key stats
About Franklin Genomic Advancements ETF
Expense ratio
0.50%
Home page
Inception date
Feb 25, 2020
HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.
Classification
What's in the fund
Exposure type
Health Technology
Commercial Services
Stock breakdown by region